Pleural
Reliably making the primary diagnosis of mesothelioma utilizing serous fluid cytology specimens: an institutional experience
Journal of the American Society of Cytopathology 2024 March 2 [Link] Terri E Jones, Daniel L Geisler, Swikrity Upadhyay Baskota, N Paul Ohori, Jacqueline Cuda, Samer N Khader Abstract Introduction: The diagnosis of mesothelioma has historically been challenging, especially on serous fluid cytology (SFC). Distinguishing between reactive and neoplastic mesothelial cells can be difficult on…
Read MoreInvestigation of the appropriate viscosity of fibrinogen in repairing pleural defects using ventilation and anchoring in an ex vivo pig model
Journal of Cardiothoracic Surgery 2024 March 21 [Link] Akihiro Fukuda, Masaki Hashimoto, Yoshitaka Takegawa, Nobuyuki Kondo, Seiki Hasegawa Abstract Objective: Our previous study revealed that the viscosity of fibrinogen could influence the effectiveness of ventilation and anchoring (V/A) methods for controlling air leakages. Here, we examined the association between the viscosity of fibrinogen and effectiveness…
Read MoreCharacterization of KLHL14 anti-oncogenic action in malignant mesothelioma
Heliyon 2024 March 9 [Link] Angelo Canciello, Reyes Benot Domínguez, Barbara Barboni, Antonio Giordano, Andrea Morrione Abstract Malignant mesothelioma (MM) is a very aggressive neoplasia with a short life expectancy and limited therapeutic options. Thus, the identification of novel molecular targets is a matter of great urgency. Kelch-like (KLHL) proteins play an important role in…
Read MoreComplex Genomic Rearrangement Patterns in Malignant Pleural Mesothelioma due to Environmental Asbestos Exposure
Journal of Environmental Pathology, Toxicology, and Oncology 2024 [Link] Tunç Tuncel, Güntülü Ak, Hasan Veysi Güneş, Muzaffer Metintaş Abstract Malignant pleural mesothelioma (MPM) is a rare type of cancer, and its main risk factor is exposure to asbestos. Accordingly, our knowledge of the genomic structure of an MPM tumor is limited when compared to other…
Read MoreImmune modulation in malignant pleural effusion: from microenvironment to therapeutic implications
Cancer Cell International 2024 March 12 [Link] Shan Ge, Yuwei Zhao, Jun Liang, Zhongning He, Kai Li, Guanghui Zhang, Baojin Hua, Honggang Zheng, Qiujun Guo 2, Runzhi Qi, Zhan Shi Abstract Immune microenvironment and immunotherapy have become the focus and frontier of tumor research, and the immune checkpoint inhibitors has provided novel strategies for tumor…
Read MorePleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer
Molecular Oncology 2024 March 8 [Link] Manuel Rigon, Luciano Mutti, Michelangelo Campanella Abstract Mesothelioma is a type of late-onset cancer that develops in cells covering the outer surface of organs. Although it can affect the peritoneum, heart, or testicles, it mainly targets the lining of the lungs, making pleural mesothelioma (PMe) the most common and…
Read MoreUV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial
European Journal of Cancer 2024 March 1 [Link] Vilde Drageset Haakensen, Åsa Kristina Öjlert, Solfrid Thunold, Saima Farooqi, Anna K Nowak, Wee L Chin, Oscar Grundberg, Weronika Maria Szejniuk, Susana Cedres, Jens Benn Sørensen, Tonje Sofie Dalen, Marius Lund-Iversen, Maria Bjaanæs, Åslaug Helland Abstract Purpose: The NIPU-trial investigates the effect of adding the telomerase vaccine…
Read MorePOLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma
Cancer Genomics & Proteomics 2024 March-April [Link] Daiki Shimizu, Miku Ishibashi, Tadaaki Yamada, Yuki Toda, Shigekuni Hosogi, Eishi Ashihara Abstract Background/aim: The prognosis of patients with malignant pleural mesothelioma (MPM) remains poor due to lack of effective therapeutic targets. DNA damage caused by long-time exposure to asbestos fibers has been associated with the development of…
Read MoreThe highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition
Translational Oncology 2024 May [Link] Claudia Kalla, German Ott, Francesca Finotello, Karolina Niewola-Staszkowska, Giusy Di Conza, Michael Lahn, Lars van der Veen, Julia Schüler, Roger Falkenstern-Ge, Joanna Kopecka, Chiara Riganti Abstract Targeting aberrantly expressed kinases in malignant pleural mesothelioma (MPM) is a promising therapeutic strategy. We here investigated the effect of the novel and highly…
Read MoreThe genetic susceptibility in the development of malignant pleural mesothelioma: somatic and germline variants, clinicopathological features and implication in practical medical/surgical care: a narrative review
Journal of Thoracic Disease 2024 January 30 [Link] Maria Teresa Congedo, Elizabeth Casey West, Jessica Evangelista, Aubrey Anne Mattingly, Giuseppe Calabrese, Carolina Sassorossi, Adriana Nocera, Marco Chiappetta, Sara Flamini, Ludovico Abenavoli, Stefano Margaritora, Luigi Boccuto, Filippo Lococo Abstract Background and objective: Malignant pleural mesothelioma (MPM) is a very aggressive primary tumor of the pleura whose…
Read More